Acumen Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABOS research report →
Range $7 – $7
Price Chart
About the company
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.
- CEO
- Daniel J. O'Connell
- IPO
- 2021
- Employees
- 61
- HQ
- Newton, MA, US
Get TickerSpark's AI analysis on ABOS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.49M
- P/E
- -0.15
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.48
- EV/EBITDA
- 0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -166.49%
- ROIC
- -172.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-123,832,000
- Net Income
- $-121,335,000-18.6%
- EPS
- $-2.00-17.0%
- OCF Growth
- -34.0%
- FCF Growth
- -34.1%
- 52W High
- $3.60
- 52W Low
- $0.16
- 50D MA
- $1.62
- 200D MA
- $2.36
- Beta
- 0.33
- RSI (14)
- 22
- Avg Volume
- 2.70M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Acumen said it expects Phase II ALTITUDE-AD results for sabirnetug in November, with cash runway into early 2027 and a clear clinical bar centered on 30% slowing on iADRS.· October 26, 2026
- Phase II ALTITUDE-AD topline data for sabirnetug is expected in November, including efficacy, safety, and biomarker readouts.
- Management reiterated a target of 30% slowing on iADRS after 18 months as the benchmark for moving forward.
- The company highlighted high rollover into the 12-month open-label extension, with greater than 95% of eligible patients consenting.
- Cash and marketable securities were approximately $79 million at quarter-end, expected to fund current activities into early 2027.
- Acumen also advanced its next-generation EBD program, citing encouraging brain-exposure data and an IND filing expected in mid-2027.
Acumen ended the third quarter with approximately $79 million in cash and marketable securities, expected to support current clinical and operational activities into early 2027. R&D expense was $21.1 million, down year over year mainly due to lower manufacturing/materials and CRO costs tied to ALTITUDE-AD. G&A expense was $4.7 million, roughly flat year over year. The company reported a loss from operations of $25.8 million and a net loss of $25.4 million. Forward, management said the Phase II ALTITUDE-AD topline data will be announced in November and that the readout will include primary and secondary efficacy, safety, and biomarker results; the open-label extension is expected to continue generating data into 2027.
Dan O'Connell framed the quarter as a lead-up to a major clinical catalyst, emphasizing that ALTITUDE-AD is a large, well-powered test of the company’s amyloid-beta oligomer hypothesis. He said sabirnetug’s differentiated profile could support a selective benefit-to-risk case, and he pointed to the study’s design as suitable for a potential registration package with one confirmatory Phase III after positive Phase II results. He also sounded constructive on the broader pipeline, saying the EBD program and upcoming sabirnetug readout create multiple value-creating milestones ahead.
Matt Zuga focused on runway and quarterly spend. He said the company had approximately $79 million in cash and marketable securities at September 30, 2026, which should fund current clinical and operational activities into early 2027. He reported R&D expense of $21.1 million, driven lower by reduced manufacturing/materials and CRO costs for ALTITUDE-AD, G&A of $4.7 million, and a loss from operations of $25.8 million with a net loss of $25.4 million.
Analysts focused heavily on what would constitute success in ALTITUDE-AD, including the minimum efficacy bar, safety expectations, and whether biomarker data could help validate the oligomer hypothesis. Management said it has been guiding to 30% slowing on iADRS after 18 months, expects low double-digit ARIA-E overall, and believes the topline package will be broad enough to inform a Phase III path if results are positive. Questions also probed whether sabirnetug could work as a maintenance or post-plaque-clearance therapy, and management said that would be a logical extension of the mechanism. On development strategy, management said retention has exceeded expectations, missing data would be handled conventionally, and a subcutaneous option could be advanced later, potentially similar to how other Alzheimer’s programs incorporated subcu in Phase III/open-label extension.
The company is about to disclose the first pivotal-style clinical test of its oligomer hypothesis, which management believes could differentiate sabirnetug from plaque-focused approaches. Management sounded confident about trial execution, retention, and the completeness of the upcoming dataset, and it pointed to high rollover into open-label extension as a positive sign. The EBD program also showed promising preclinical brain-exposure results, adding another potential long-term driver.
The biggest risk is that the upcoming Phase II data may not meet the company’s implied bar of 30% slowing on iADRS or may not produce a convincing safety/biomarker package. Management acknowledged that the results are still blinded and that the study is a first test of the oligomer hypothesis, which means the science remains unproven clinically. Cash is not abundant, and the company said its current balance only funds operations into early 2027, so the readout is highly consequential for the next development step.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.4%
- Shares Outstanding
- 72.33M
- Float Shares
- 61.76M
of shares held by institutions
99 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 20.99M | 0 |
| Sands Capital Alternatives, LLC | 3.72M | 0 |
| Blackrock, Inc. | 2.80M | ▲ 311.91K |
| Alyeska Investment Group, L.P. | 2.45M | 0 |
| Franklin Templeton Inc | 2.31M | 0 |
| Adar1 Capital Management, LLC | 2.11M | ▼ 45.00K |
| Vanguard Capital Management LLC | 1.82M | ▲ 144.37K |
| Vanguard Group Inc | 1.65M | ▲ 2.30K |
| Knollwood Investment Advisory, LLC | 1.63M | 0 |
| Geode Capital Management, LLC | 1.15M | ▲ 13.06K |
| Ikarian Capital, LLC | 1.05M | 0 |
| Hudson Bay Capital Management LP | 1.02M | ▲ 70.00K |
Held by 84 ETFs
Biggest fund positions in ABOS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Porter Derrell | other | 6,460 |
| Jun 17, 26 | Porter Derrell | other | 13,040 |
| Jun 15, 26 | Porter Derrell | sell | 6,460 |
| Jun 17, 26 | Porter Derrell | sell | 13,040 |
| Jun 16, 26 | Porter Derrell | sell | 12,800 |
| Jun 15, 26 | Porter Derrell | other | 6,460 |
| Jun 17, 26 | Porter Derrell | other | 13,040 |
| Jun 9, 26 | Fountain Nathan B | sell | 6,400 |
| Jun 3, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 53,250 |
| Jun 3, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 35,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABOS coverage
Recent articles, reports, and earnings notes.
No research on ABOS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABOS report →Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 4
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint
globenewswire.com · Oct 30
Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout
seekingalpha.com · Oct 28
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 26
Acumen Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Oct 26
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
globenewswire.com · Oct 26
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
globenewswire.com · Oct 22
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
globenewswire.com · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.